Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|9|4|365-376

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.9, Iss.4, 2014-11, pp. : 365-376

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

No link between MMR vaccine and pervasive developmental disorders

By  

Reactions Weekly, Vol. 1, Iss. 1019, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Atypical Antipsychotics in Children with Pervasive Developmental Disorders

By Chavez Benjamin   Chavez-Brown Mapy  

Pediatric Drugs, Vol. 9, Iss. 4, 2007-01 ,pp. : 249-266

Adis International

Access to resources Recommend Favorite

Advances in the Pharmacotherapy of Pervasive Developmental Disorders (PDD)

By  

Child and Adolescent Psychopharmacology News, Vol. 8, Iss. 7, 2003-11 ,pp. : 6-11

Guilford Publications Inc

Access to resources Recommend Favorite

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

By Malone Richard P.   Gratz Silvia S.   Mary Anne Delaney   Hyman Susan B.  

CNS Drugs, Vol. 19, Iss. 11, 2005-01 ,pp. : 923-934

Adis International

Access to resources Recommend Favorite

Focus: The Use of Psychotropic Drugs in Autism and Other Pervasive Developmental Disorders

By  

Child and Adolescent Psychopharmacology News, Vol. 14, Iss. 2, 2009-04 ,pp. : 1-9

Guilford Publications Inc

Access to resources Recommend Favorite